Convertissez BioHash BIOHASH en Super OETH SUPEROETHB

BioHash is a decentralized science (DeSci) protocol that builds a transparent on-chain infrastructure for tracking, validating, and pricing biotech and peptide-related data using blockchain technology and AI-assisted systems. At its core, BioHash functions as a real-time oracle layer that converts fragmented off-chain biological and pharmaceutical data (such as vendor pricing, peptide availability, and observational research inputs) into structured, verifiable on-chain commitments. These updates are aggregated through TWAP (time-weighted average price) cycles and anchored to Solana, creating a cryptographically auditable record of live market and research conditions. Each update cycle produces a Merkle-rooted proof of the dataset, which is stored on-chain for integrity, while full provenance data (including sources, timestamps, and statistical adjustments) is made available via decentralized storage. This ensures full transparency, reproducibility, and resistance to manipulation. BioHash is designed to support autonomous scientific and health-focused agents that continuously evaluate new data, run validation checks, and surface emerging signals across the DeSci ecosystem. Over time, this enables a permissionless, data-driven marketplace for bioinformatics, peptide research, and real-world biochemical pricing intelligence. The BioHash ecosystem is currently expanding through indexed peptides, vendor onboarding, and staged validation phases before full inclusion into the oracle network.

Origin’s expansion to Base introduces a new class of supercharged LSTs to accrue value to OGN. Super OETH will be the first token of its kind to offer a high yield on ETH with minimal risk. Instead of simply bridging Origin Ether to Base, we’ve designed a new supercharged LST that uses OETH as a building block for higher yields. Super OETH uses L2 incentives to enhance LST yield, earning far higher APYs than traditional LSTs. Our new product is the first supercharged LST, slated to launch on Base with additional L2s in the pipeline for this year.